BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 1534096)

  • 1. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
    J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS; Anasetti C; Tso JY
    J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
    J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
    Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
    Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
    Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
    J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
    J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
    Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
    Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
    Ferran C; Dy M; Sheehan K; Schreiber R; Grau G; Bluestone J; Bach JF; Chatenoud L
    Eur J Immunol; 1991 Oct; 21(10):2349-53. PubMed ID: 1833202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature requirements and kinetics of T cell signaling. Velocity of triggering correlates with functional effects of anti-CD3 mAb.
    Abdi K; Reed ML; Mentzer SJ; Herrmann SH
    J Immunol; 1989 May; 142(9):2971-80. PubMed ID: 2468707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanization of the murine anti-human CD3 monoclonal antibody OKT3.
    Adair JR; Athwal DS; Bodmer MW; Bright SM; Collins AM; Pulito VL; Rao PE; Reedman R; Rothermel AL; Xu D
    Hum Antibodies Hybridomas; 1994; 5(1-2):41-7. PubMed ID: 7858182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
    Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
    J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of epidermal Langerhans cell function by low dose ultraviolet B radiation. Ultraviolet B radiation selectively modulates ICAM-1 (CD54) expression by murine Langerhans cells.
    Tang A; Udey MC
    J Immunol; 1991 May; 146(10):3347-55. PubMed ID: 1673983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex.
    Ceuppens JL; Bloemmen FJ; Van Wauwe JP
    J Immunol; 1985 Dec; 135(6):3882-6. PubMed ID: 2933454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
    Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
    Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.
    Alegre ML; Vandenabeele P; Depierreux M; Florquin S; Deschodt-Lanckman M; Flamand V; Moser M; Leo O; Urbain J; Fiers W
    J Immunol; 1991 Feb; 146(4):1184-91. PubMed ID: 1825107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.